Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05389462 · ClinicalTrials.gov registry record · Phase 1
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
A Phase 1 study, sponsored by ADC Therapeutics S.A..
- Terminated
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT05389462 is a Phase 1 study that was terminated before completion, run by ADC Therapeutics S.A.. The registered enrollment target is 128 participants.
The verdict
NCT05389462, a Phase 1 study, was terminated before completion, sponsored by ADC Therapeutics S.A..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.
Interventions
- DRUG Gemcitabine
- DRUG ADCT-601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2022-07-13 |
| Est. Completion | 2025-04-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05389462
The ClinicalTrials.gov registry entry for NCT05389462 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT05389462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05389462 about?
NCT05389462 is a clinical study titled "A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors". The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.
What is the current status of trial NCT05389462?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2022-07-13. Estimated completion is 2025-04-17.
What interventions are being tested in trial NCT05389462?
The interventions under investigation include: Gemcitabine (DRUG), ADCT-601 (DRUG).
Who is sponsoring clinical trial NCT05389462?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.